HCW Biologics Inc. (NASDAQ:HCWB) Stock Short Interest Drops 72.8%

HCW Biologics Inc. (NASDAQ:HCWB) was the target of a large drop in short interest in September. As of September 15th, there was short interest totaling 9,274 shares, a drop of 72.8% from the August 31st total of 34,136 shares. Currently, 0.6% of the shares of the stock are short sold. Based on an average trading volume of 414,337 shares, the short-interest ratio is currently 0.0 days.

HCW Biologics Stock Performance

NASDAQ HCWB traded down $0.14 during trading hours on Monday, hitting $1.79. 56,471 shares of the company’s stock were exchanged, compared to its average volume of 1,305,016. The business’s 50 day moving average is $2.72 and its 200-day moving average is $4.37. HCW Biologics has a 12-month low of $1.50 and a 12-month high of $29.28. The firm has a market capitalization of $3.30 million, a P/E ratio of -0.07 and a beta of 2.37.

HCW Biologics (NASDAQ:HCWB) last posted its earnings results on Friday, August 14th. The company reported ($11.58) EPS for the quarter, missing the consensus estimate of ($1.98) by ($9.60). The business had revenue of $0.14 million during the quarter, compared to analyst estimates of $0.14 million. HCW Biologics had a negative net margin of 83.03% and a negative return on equity of 262.33%.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of HCW Biologics in a report on Friday, July 17th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $30.00.

About HCW Biologics

HCW Biologics Inc is a clinical-stage biotechnology company focused on developing immunotherapies for diseases associated with chronic, low-grade inflammation, including cancer and age-related conditions. The company’s approach is designed to restore immune balance by reducing harmful inflammation while enhancing the body’s ability to generate an effective immune response.

HCW Biologics uses its proprietary Tissue-based Optimized Biologics Immunotherapy (TOBI™) platform to create engineered fusion-protein therapeutics.